Formulary guidance and transparency from P&T to point of care

MMIT Reality Check on Acute Myeloid Leukemia (Apr 2021)

Posted by Matt Breese on Apr 9, 2021

Find me on:

According to our recent payer coverage analysis for acute myeloid leukemia treatments, combined with news from key healthcare influencers, market access is shifting in this drug landscape.

To help make sense of this new research, MMIT's team of experts analyzes the data and summarizes the key findings for you. The following are brief highlights. To read the full piece, including payer coverage, drug competition and prescriber trends, click here.

Payer Coverage: A review of market access for acute myeloid leukemia treatments shows that under the pharmacy benefit, about 65% of the lives under commercial formularies are covered with utilization management restrictions.

MMIT-Reality Check-AML-2Q2021Data snapshot as of Q2 2020

Trends: In October 2020, the FDA gave full approval to AbbVie Inc. and Roche Group unit Genentech USA, Inc.’s Venclexta (venetoclax) in combination with azacitidine, decitabine or low-dose cytarabine for the treatment of newly diagnosed acute myeloid leukemia in people at least 75 years old or who have comorbidities that preclude the use of intensive induction chemotherapy.  

To read the full Reality Check on Acute Myeloid Leukemia treatments with key findings on clinical characteristics, drug market access and payer coverage, please click on the button below: 


View Reality Check

Topics: Specialty, Market Access, Payer, Branding & Marketing